- Sector
- Healthcare
- Industry
- Biotechnology
- IPO Date
- Nov 16, 2020
Highlights
- Market Cap
- $58.06K
- Enterprise Value
- -$13.18M
- EPS (TTM)
- -$7.21
- Gross Profit (TTM)
- -$19.84K
- EBITDA (TTM)
- -$10.01M
- Year Range
- $0.01 - $0.04
- ROA (TTM)
- -103.38%
- ROE (TTM)
- -119.74%
- Avg. Volume (1M)
- 7K
- Avg. Volume Value (1M)
- $66.11
Share Price Chart
Loading charts...
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
REVBW Performance Chart
Revelation Biosciences Inc (REVBW) is up 22.5% since the beginning of the year. At $0 per share, REVBW is trading 75.4% below its 52-week high of $0. Investors who bought $1,000 worth of REVBW shares 5 years ago would now be looking at an investment worth $14.
Loading charts...
Compare this symbol against anything
Returns By Period
Revelation Biosciences Inc (REVBW) has returned 22.50% so far this year and -43.02% over the past 12 months.
Revelation Biosciences Inc
- 1D
- 0.00%
- 1M
- 50.77%
- 6M
- -14.78%
- YTD
- 22.50%
- 1Y
- -43.02%
- 3Y*
- -15.94%
- 5Y*
- -57.50%
- 10Y*
- —
- ALL TIME*
- -45.12%
Benchmark (S&P 500 Index)
- 1D
- 0.70%
- 1M
- 0.09%
- 6M
- 7.94%
- YTD
- 9.41%
- 1Y
- 20.07%
- 3Y*
- 17.84%
- 5Y*
- 11.25%
- 10Y*
- 13.26%
- ALL TIME*
- 8.09%
REVBW Monthly Returns History
Based on dividend-adjusted daily data since Nov 16, 2020, REVBW's average daily return is +0.75%, while the average monthly return is +3.86%. At this rate, an investment would double in approximately 1.5 years.
Historically, 43% of months were positive and 57% were negative. The best month was Feb 2024 with a return of +193.3%, while the worst month was Jan 2022 at -73.5%. The longest winning streak lasted 4 consecutive months, and the longest losing streak was 5 months.
On a daily basis, REVBW closed higher 39% of trading days. The best single day was May 15, 2026 with a return of +170.0%, while the worst single day was Dec 28, 2022 at -49.4%.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 43.75% | -13.04% | -9.00% | -12.09% | 75.00% | -43.57% | 24.05% | 22.50% | |||||
| 2025 | 130.00% | 6.21% | -36.56% | 24.44% | -11.85% | 0.84% | 45.83% | -14.86% | -16.10% | -5.60% | -15.25% | -20.00% | 14.29% |
| 2024 | -29.25% | 193.33% | 20.45% | -46.04% | -11.19% | 57.48% | -39.00% | 13.94% | 7.91% | -14.67% | -4.69% | -42.62% | -33.96% |
| 2023 | 119.85% | 12.15% | -49.85% | -6.79% | 30.46% | -9.64% | -15.74% | 20.00% | -6.11% | -28.99% | -19.17% | 9.28% | -19.08% |
| 2022 | -73.53% | -26.89% | -1.60% | -18.07% | -34.02% | 13.71% | 50.75% | -57.67% | -17.32% | -25.71% | -3.85% | -56.33% | -98.07% |
| 2021 | 2.25% | 8.79% | -47.47% | 25.00% | -4.88% | 3.51% | 10.47% | -36.34% | 37.97% | -3.38% | 6.37% | 6.55% | -23.60% |
Benchmark Metrics
Revelation Biosciences Inc has an annualized alpha of 503.50%, beta of 0.56, and R2 of 0.00 versus S&P 500 Index. Calculated based on daily prices since November 16, 2020.
- This stock participated in 269.39% of S&P 500 Index downside but only 146.62% of its upside - more exposed to losses than it benefited from rallies.
- Beta of 0.56 may look defensive, but with R2 of 0.00 this stock is largely uncorrelated with S&P 500 Index - low beta reflects independence, not downside protection. See the Volatility section for a true picture of this stock's risk.
- R2 of 0.00 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.
- Alpha
- 503.50%
- Beta
- 0.56
- R²
- 0.00
- Upside Capture
- 146.62%
- Downside Capture
- 269.39%
Return for Risk
Risk / Return Rank
REVBW ranks 46 for risk / return — above 46% of stocks peers on PortfoliosLab. Its historical combined result is near the middle of the peer group.
Risk / Return Metrics
The table below present risk-adjusted performance metrics for Revelation Biosciences Inc (REVBW) and compare them to S&P 500 Index.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| REVBW | Benchmark | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -1.59 | ||
| Sortino ratioReturn per unit of downside risk | -0.41 | ||
| Omega ratioGain probability vs. loss probability | 1.25 | 1.25 | -0.01 |
| Calmar ratioReturn relative to maximum drawdown | -0.59 | 2.00 | -2.60 |
| Martin ratioReturn relative to average drawdown | -0.95 | 8.49 | -9.44 |
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading charts...
Worst Drawdowns
The table below displays the maximum drawdowns of the Revelation Biosciences Inc. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Revelation Biosciences Inc was 99.64%, occurring on Apr 28, 2026. The portfolio has not yet recovered.
The current Revelation Biosciences Inc drawdown is 99.30%.
Drawdown | Fall | Recovery | Underwater | Related event |
|---|---|---|---|---|
-99.64%Apr 2026 | 5y 2mo | — | 5y 5moFeb 2021 - now | — |
-31.58%Jan 2021 | 10d | 21d | 1mo 1dJan 2021 - Feb 2021 | — |
-26.13%Dec 2020 | 1d | 26d | 27dDec 2020 - Dec 2020 | — |
-17.88%Jan 2021 | 6d | 9d | 15dDec 2020 - Jan 2021 | — |
-13.33%Nov 2020 | 1d | 2d | 2dNov 2020 - Nov 2020 | — |
Drawdown Indicators
| REVBW | Benchmark | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -99.64% | -56.78% | -42.86% |
Max Drawdown (1Y)Largest decline over 1 year | -74.75% | -9.10% | -65.65% |
Max Drawdown (3Y)Largest decline over 3 years | -83.33% | -18.90% | -64.43% |
Max Drawdown (5Y)Largest decline over 5 years | -99.32% | -25.43% | -73.89% |
Max Drawdown (10Y)Largest decline over 10 years | — | -33.92% | — |
Current DrawdownCurrent decline from peak | -99.30% | -1.58% | -97.72% |
Average DrawdownAverage peak-to-trough decline | -87.20% | -10.70% | -76.50% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 46.68% | 2.14% | +44.54% |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading charts...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of Revelation Biosciences Inc over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Valuation
The Valuation section provides an overview of how Revelation Biosciences Inc is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PB Ratio
The chart illustrates the Price-to-Book (P/B) ratio for REVBW in comparison with other companies in the Biotechnology industry. Currently, REVBW has a P/B value of 0.0. This P/B ratio is low compared to industry peers. It might indicate the stock is undervalued or that the company’s assets are not expected to generate strong returns.
Income Statement
| TTM | |
|---|---|
Revenue | |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |
Build a portfolio with REVBW
Add Revelation Biosciences Inc to a portfolio and analyze allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Analyzer with REVBW